The stock has witnessed one upward estimate revision in the past 30 days. The Zacks Consensus Estimate has also moved up over the same time frame, suggesting that more solid trading could be ahead for Rexahn Pharmaceuticals. So make sure to keep an eye on this stock going forward to see if the latest jump can turn into more strength down the road.
Rexahn Pharmaceuticals hold a Zacks Rank #2 (Buy), while its Earnings ESP is 0.00%.
However, some better-ranked stocks in the med-biomed/gene industry include Biogen Idec Inc. (BIIB), Affymetrix Inc. (AFFX) and NI Pharmaceuticals, Inc. (ANIP), all sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment